“By enhancing our BD FACSymphony™ A5 instrument technology with spectral-enabling capabilities, we are responding to the expressed needs of our customers and laboratories, who want the flexibility to perform both conventional and spectral flow cytometry analyses on a single instrument,” said Puneet Sarin, worldwide president of BD Biosciences. “Offering an analyzer with both spectral unmixing and compensation-based cell analysis gives customers the ability to transition to spectral analysis as needed and as their users are ready.”

With spectral unmixing, researchers have access to expanded dye capabilities to build larger panels or ease panel design efforts. Compensation-based analysis supports labs with existing protocols and users not ready to fully move to spectral analysis.

Spectral flow cytometry represents an alternative data acquisition and analysis strategy to conventional flow cytometry, providing flexibility of fluorescent label inputs without having to change filters, as well as the ability to multiplex more fluorescent labels in one multicolor sample. Spectral unmixing is a procedure that calculates the amount of each fluorophore present on a cell based on the full emission profile of each individual fluorochrome.

For more information or to request a demo, visit our BD FACSymphony™ A5 SE Cell Analyzer page.